You are here » About Galderma » Company History

Company History

Dermatology company Galderma’s detailed timeline:

2014

 

Foundation of Nestlé Skin Health. Galderma is now fully-owned by Nestlé.
Galderma enters into an agreement with Valeant, through which Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.

2013

 

Acquisition of Swiss company Spirig AG, maker of Daylong & Excipial.
FDA approval of Mirvaso for the treatment of erythema associated with rosacea.

2012

 

Galderma defines its new 3-business-strategy and a new ambition statement.
Opening of a new affiliate in China.
Cetaphil Dermacontrol is launched in 6 countries.

2011

 

Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Launch of Cetaphil Restoraderm.
Plant extensions in France and Canada. Differin Lotion 0.1% (acne) launch in the United States.
Galderma hits the 1 billion mark in sales.

2010

 

Launch of Azzalure (glabellar lines) and Oracea in Europe.

2009

 

Vectical (psoriasis) launch in the United-States.

2008

 

Epiduo (acne) launch.
Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea). Launch of Differin 0.1% in Japan.

2007

 

Licensing agreements for abotulinum toxin type A and Pliaglis (topical anesthetic).
Differin 0.3% launch.

2006

 

Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.

2005

 

Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).

2004

 

Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.

2003

 

Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US.

2002

 

Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.

2001

 

Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment).
Launch of Clindagel (anti-acne).

2000

 

The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).

1999

 

Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.

1998

 

Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.

1997

 

Acquisition of Basotherm, a subsidiary of Boehringer.

1996

 

Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.

1995

 

Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.

1994

 

Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.

1993

 

Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.

1989

 

Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.

1988

 

Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.

1986

 

Galderma’s firstaffiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.

1981

 

Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.

1979

 

L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.

1977

 

Nestlé acquires Alcon to strengthen its presence in the North Americanmarket.

1972

 

Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.

1961

 

Creation of the Owen dermatology company in Dallas, Texas, USA.

 

 Discover more about Galderma, a dermatology company providing dermatology solutions and aesthetic and corrective products internationally.

Follow us Follow us on twitter Follow us on Linkedin

Corporate responsibility

Growing a responsible dermatological community

Discover some of the positive initiatives we are involved in across the world

Read